ArticleJournal of the Royal Society, Interface2026
A multi-objective sequence engineering framework for rational genetic vaccine design.
Article in Journal of the Royal Society, Interface, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A multi-objective sequence engineering framework for rational genetic vaccine design.Journal of the Royal Society, Interface · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Genetic vaccine performance is determined not only by the delivery platforms and antigen choice but also by the coding sequence that influences antigen expression, innate immune sensing, transcript stability and sequence-associated risks. However, the design principles governing these sequence-level effects remain insufficiently defined. Thus, we consider vaccine coding-sequence design as a multi-objective engineering problem that requires simultaneous consideration of multiple, potentially competing biological properties. We present a multi-parameter computational framework for analysing SARS-CoV-2 vaccine coding sequences, including BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), AZD1222 (AstraZeneca) and several academic vaccine candidates. The framework evaluates codon usage, codon-pair context, CpG content, regulatory motifs, GC content and localized sequence-structural features within a unified quantitative design space. Our analysis shows that existing vaccines use diverse design strategies and that no single metric adequately captures their design complexity. By enabling systematic comparison across multiple parameters, the framework supports the rational generation and prioritization of candidate sequences with defined biological trade-offs. This work bridges computational sequence analysis, vaccine biology and engineering design, providing a foundation for context-aware optimization of genetic vaccine sequences across delivery platforms, target tissues and emerging pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.